Long-term follow up of Hodgkin lymphoma
Entity
UAM. Departamento de MedicinaPublisher
Impact JournalsDate
2018-02-20Citation
10.18632/oncotarget.24392
Oncotarget 9.14 (2018): 11638-11645
ISSN
1949-2553DOI
10.18632/oncotarget.24392Editor's Version
https://doi.org/10.18632/oncotarget.24392Subjects
Hodgkin lymphoma; Standardized mortality ratio; Survival; MedicinaRights
© Perez-Callejo et alAbstract
Background: Hodgkin lymphoma (HL) is the paradigm of curable disease. This study analyzed the overall survival (OS) of patients with HL and compared their survival between decades and with the expected survival of a general population. Results: The median follow-up was 22 years. The median OS was 33 years. The incidence mortality rate for all causes is 2 per every 100 patients per year. The OS of our cohort at 10 years from diagnosis was 76% (95% CI: 72-79) and 52% at 30 years (95% CI: 48-57). Overall SMR (1980-2013) was 2,943 (95% CI: 2,518-3,439). Excluding the primary tumor as the cause of death, the SMR obtained is 2,266 (95% CI: 1,895-2,710). The SMR for those patients diagnosed before the year 2000 was 2,097 (95% CI: 1,732-2,539); and for those diagnosed after 2000 was 5,218 (95% CI: 8,655). The group of patients diagnosed after 2000 had statistically significant more advanced stages, were older and less responsive to treatment. Conclusions: Despite the advances achieved, the risk of death remains higher than in the general population, mainly for those patients diagnosed after year 2000, even after almost 40 years of follow-up. This data might suggest a shift to more aggressive forms of disease in recent years. Patients and methods: A total of 595 patients diagnosed with HL were included between January 1966 and February 2014. The standardized mortality ratio (SMR) was analyzed using the annual rate of mortality in the general Spanish population, adjusted for age, sex and time period.
Files in this item
Google Scholar:Pérez-Callejo, David
-
Zurutuza, Lorea
-
Royuela Vicente, Ana
-
Torrente, María
-
Núñez, Beatriz
-
Calvo de Juan, Virginia
-
Méndez, Miriam
-
Franco, Fernando
-
Brenes, María Auxiliadora
-
Sánchez, Juan Cristobal
-
Provencio Pulla, Mariano
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
Provencio Pulla, Mariano; Pérez-Callejo, David; Torrente, María; Martín, Paloma; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Franco, Fernando; Coronado, María José; Cruz-Bermúdez, Juan Luis; Martín Ruiz-Valdepeñas, Asunción; Cruz-Bermúdez, Alberto; Sánchez-Beato, Margarita; Romero, Atocha; García-Grande, Aránzazu
2017-07-31 -
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
Provencio Pulla, Mariano; Torrente, María; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Pérez-Callejo, David; Pérez-Barrios, Clara; Barquín, Miguel; Royuela Vicente, Ana; Rodríguez-Alfonso, Begoña; Sotelo, Miguel; Cruz-Bermúdez, Juan Luis; Mendez, Miriam; Cruz-Bermúdez, Alberto; Romero, Atocha
2017-08-07